Amid Trump Cost-Cutting Plans, GAO Warns FDA Needs To Invest In Inspection Workforce

Even as the next presidential administration plans massive spending and staffing reductions for federal health agencies, a new report from the Government Accountability Office (GAO) warns FDA’s ability to monitor drug safety will be harmed if the agency doesn’t take steps to retain facility inspectors it’s previously written off as too costly, like reducing travel time and improving work-life balance. Likewise, a drug industry lawyer warns that HHS-nominee Robert F. Kennedy Jr.’s goal of resurrecting FDA’s “gold standard” of drug...